Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells
9.0
来源：
Cell
发布时间：
2025-08-30 03:32
摘要：
AlloCAR70-NKT cells, engineered from hematopoietic stem and progenitor cells, target CD70 in metastatic renal cell carcinoma (RCC). This innovative therapy demonstrates robust antitumor activity through multimodal mechanisms, effectively overcoming tumor immune evasion. The study highlights the cells' ability to deplete immunosuppressive tumor-associated macrophages and maintain safety with reduced risk of cytokine release syndrome. These findings position AlloCAR70-NKT cells as a promising off-the-shelf immunotherapy for RCC, with significant implications for future clinical applications.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
1.0分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.5分
technical_barrier_competition
1.0分
关键证据
AlloCAR70-NKT cells exhibit potent cytotoxicity against primary and metastatic RCC.
The study demonstrates the ability of AlloCAR70-NKT cells to target both tumor cells and the immunosuppressive tumor microenvironment.
AlloCAR70-NKT cells show a favorable safety profile with minimal risk of cytokine release syndrome.
真实性检查
否
AI评分总结
AlloCAR70-NKT cells, engineered from hematopoietic stem and progenitor cells, target CD70 in metastatic renal cell carcinoma (RCC). This innovative therapy demonstrates robust antitumor activity through multimodal mechanisms, effectively overcoming tumor immune evasion. The study highlights the cells' ability to deplete immunosuppressive tumor-associated macrophages and maintain safety with reduced risk of cytokine release syndrome. These findings position AlloCAR70-NKT cells as a promising off-the-shelf immunotherapy for RCC, with significant implications for future clinical applications.